Leeward Investments LLC MA Acquires 142,007 Shares of Option Care Health, Inc. $OPCH

Leeward Investments LLC MA grew its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 20.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 848,059 shares of the company’s stock after buying an additional 142,007 shares during the quarter. Leeward Investments LLC MA owned 0.57% of Option Care Health worth $19,073,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of OPCH. Reyes Financial Architecture Inc. bought a new stake in shares of Option Care Health in the 3rd quarter valued at about $28,000. Harbor Investment Advisory LLC purchased a new stake in Option Care Health during the 2nd quarter valued at about $48,000. Nykredit A S bought a new position in Option Care Health during the 2nd quarter worth approximately $56,000. Nisa Investment Advisors LLC grew its position in Option Care Health by 268.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,955 shares of the company’s stock worth $66,000 after acquiring an additional 2,154 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Option Care Health during the 2nd quarter worth approximately $66,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Stock Performance

Option Care Health stock opened at $31.22 on Monday. The company has a current ratio of 1.47, a quick ratio of 0.98 and a debt-to-equity ratio of 0.91. The firm has a 50-day moving average of $25.72 and a 200-day moving average of $23.87. The firm has a market cap of $4.68 billion, a P/E ratio of 23.47, a P/E/G ratio of 1.90 and a beta of 0.58. Option Care Health, Inc. has a 1-year low of $18.01 and a 1-year high of $36.80.

Option Care Health (NASDAQ:OPCH) last posted its earnings results on Wednesday, July 29th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.02. Option Care Health had a return on equity of 18.74% and a net margin of 3.68%. The company had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.42 billion. During the same period last year, the firm earned $0.41 earnings per share. Option Care Health’s quarterly revenue was up 1.9% on a year-over-year basis. Option Care Health has set its FY 2026 guidance at 1.850-1.920 EPS. Sell-side analysts expect that Option Care Health, Inc. will post 1.70 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on OPCH shares. William Blair cut Option Care Health from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 6th. Zacks Research raised Option Care Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Citizens Jmp lowered Option Care Health from a “market outperform” rating to a “hold” rating in a research note on Wednesday, October 7th. Truist Financial set a $32.05 target price on shares of Option Care Health in a report on Wednesday, October 7th. Finally, Barrington Research cut shares of Option Care Health from an “outperform” rating to a “hold” rating in a report on Wednesday, October 7th. Two analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $29.48.

Option Care Health Profile

Option Care Health, Inc is an independent provider of home and alternate-site infusion services in the United States. The company coordinates and delivers infusion therapy outside traditional hospital settings, including patients’ homes, ambulatory infusion suites and other outpatient locations.

Its services include administration of anti-infective therapies, immune globulin, nutrition support, inotropic therapies and medications used in the treatment of chronic and complex conditions.